Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

Source Motley_fool

Key Points

  • Bristol Myers Squibb's stock is up more than 17% so far this year.

  • The company could be acquired by AstraZeneca.

  • Bristol Myers Squibb has increased its dividend for 17 consecutive years.

  • 10 stocks we like better than Bristol Myers Squibb ›

Bristol Myers Squibb (NYSE: BMY) is up a little more than 17% so far this year. Analysts don't seem that optimistic about the pharmaceutical stock, with an average price target of $66.71, just over $3 above its current trading price.

The bear case for the stock is that several of its top sellers, including Eliquis and Opdivo, are facing patent expirations. However, that's discounting the rise in the company's growth portfolio. Here are three reasons why the bull case for the stock is getting louder.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Stethoscope, syringe, and cup of pills.

Image source: Getty Images.

It's underpriced compared to its peers

The company is coming off a strong second quarter, in which it reported revenue of $12.9 billion, up 6% year over year, and earnings per share (EPS) of $1.62, up 153% from the same quarter a year ago.

Despite strong recent operating performance, the stock trades at a discounted valuation of less than 10 times forward earnings and less than 14 times trailing earnings. That's lower than most of its mega-cap pharmaceutical peers, including AbbVie, AstraZeneca, Merck, Johnson & Johnson, Pfizer, and Roche.

BMY PE Ratio (Forward) Chart
BMY PE Ratio (Forward) data by YCharts.

This suggests the market has overly discounted the stock relative to its more than $11 billion in annual free cash flow, creating a high margin of safety and rerating potential as pipeline milestones read out.

Its growth drugs, including Opdivo, Qvantig, Cobeyta, Camzyos, Reblozyl, Breyanzi, and Opdualag, now account for nearly 60% of total revenue and grew revenue by 15% year over year in the second quarter. Double-digit expansion across these commercialized therapies, combined with next-generation pipeline candidates such as blood thinner Milvexian, gives the company a clear runway to fill the top-line revenue gap.

It has a solid, well-funded dividend

Bristol Myers Squibb has paid out a dividend for 94 consecutive years and has raised it for the past 17 years. This includes a 1.6% increase to $0.63 per share this year, boosting the dividend yield to 3.95% at current prices, more than three times the average dividend yield on the S&P 500.

With a conservative payout ratio of around 44% of trailing free cash flow (FCF), the dividend is well supported by free cash flow, paying investors handsomely as the pipeline executes.

The other area where the company is shareholder-friendly is in stock buybacks. It has a $5 billion stock repurchase plan in effect.

Its cash machine gives it a nice cushion

Bristol Myers Squibb continues to beat quarterly earnings and revenue expectations, and delivered more than $3 billion in FCF in Q2. This substantial cash generation allows management to simultaneously fund late-stage research and development, pursue strategic bolt-on acquisitions, and aggressively pay down debt to strengthen the balance sheet.

Ironically, one thing that could certainly push the stock higher is another company purchasing it. According to reports, AstraZeneca and Bristol Myers Squibb held merger talks valuing Bristol Myers Squibb at $400 billion. If that deal went through, Bristol Myers Squibb, as the buyout candidate, would see its shares jump. It's worth noting that such a mega-merger would face stiff scrutiny from regulators.

Regardless of any potential mergers, Bristol Myers Squibb, like AbbVie a few years ago, is poised to offset the revenue loss from its legacy drugs with its new therapies. That likelihood hasn't yet been fully priced into the stock.

Should you buy stock in Bristol Myers Squibb right now?

Before you buy stock in Bristol Myers Squibb, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bristol Myers Squibb wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $387,158!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,365,749!*

Now, it’s worth noting Stock Advisor’s total average return is 932% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of September 20, 2026.

James Halley has positions in AbbVie, Johnson & Johnson, and Pfizer. The Motley Fool has positions in and recommends AbbVie, AstraZeneca Plc, Bristol Myers Squibb, Merck, and Pfizer. The Motley Fool recommends Johnson & Johnson and Roche Holding AG. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Anthropic Held More Cash Than Nvidia and Apple Combined Ahead of IPOAnthropic’s cash and short-term investments reached $131.7 billion on June 30, topping Nvidia and Apple combined, per CNBC. Disclosed lease and spending obligations add up to about $587 billion.Anthro
Author  Beincrypto
Oct 28, Wed
Anthropic’s cash and short-term investments reached $131.7 billion on June 30, topping Nvidia and Apple combined, per CNBC. Disclosed lease and spending obligations add up to about $587 billion.Anthro
placeholder
Morgan Stanley Says Fed Hold Today Won't End Rate HikesInvestors expect the Federal Reserve (Fed) to hold rates on Wednesday. Morgan Stanley chief US economist Michael Gapen says the Fed hold will still signal more rate hikes ahead.Markets already price a
Author  Beincrypto
Oct 28, Wed
Investors expect the Federal Reserve (Fed) to hold rates on Wednesday. Morgan Stanley chief US economist Michael Gapen says the Fed hold will still signal more rate hikes ahead.Markets already price a
placeholder
Tesla and SpaceX Stocks Fall as Investors Worry About Elon Musk’s Political RiskWhile the US stock market surged on Wednesday, SpaceX and Tesla stocks were sliding. Democrats won both chambers of Congress and the Texas governor’s race, defeats that land squarely on Elon Musk’s co
Author  Beincrypto
Nov 05, Thu
While the US stock market surged on Wednesday, SpaceX and Tesla stocks were sliding. Democrats won both chambers of Congress and the Texas governor’s race, defeats that land squarely on Elon Musk’s co
placeholder
Nvidia CEO Probe Hit Binance Stock Perps While Wall Street Was ClosedThe probe into Nvidia CEO Jensen Huang broke over the weekend, while Wall Street was closed. Crypto traders still priced it in early. Binance’s Nvidia perpetual futures fell more than 4% below the las
Author  Beincrypto
Nov 10, Tue
The probe into Nvidia CEO Jensen Huang broke over the weekend, while Wall Street was closed. Crypto traders still priced it in early. Binance’s Nvidia perpetual futures fell more than 4% below the las
placeholder
Nvidia Enters Bear Market As Google Strikes Amid Jensen Huang's China Spy WoesNvidia, the engine of the AI boom, is in a bear market. Shares sank to about $177 on Monday, 26% below their October record, as a China spy scandal reached its CEO.A bear market means a fall of 20% or
Author  Beincrypto
Nov 10, Tue
Nvidia, the engine of the AI boom, is in a bear market. Shares sank to about $177 on Monday, 26% below their October record, as a China spy scandal reached its CEO.A bear market means a fall of 20% or
goTop
quote